Telmisartan
Pronunciation: (tell-mih-SAHR-tan)Class: Angiotensin ΙΙ receptor antagonist
Trade Names:
Micardis
- Tablets 20 mg
- Tablets 40 mg
- Tablets 80 mg
Pharmacology
Antagonizes the effect of angiotensin ΙΙ (vasoconstriction and aldosterone secretion) by blocking the angiotensin ΙΙ (AT 1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.
Pharmacokinetics
Absorption
Telmisartan T max is 0.5 to 1 h after dosing. Food slightly reduces bioavailability of telmisartan, with an AUC reduction of about 6% with a 40 mg tablet and 20% with a 160 mg dose. At 40 and 160 mg, the bioavailability was 42% and 58%. Trough plasma concentrations with every day dosing are about 10% to 25% of peak plasma concentrations.
Distribution
Telmisartan is more than 99.5% protein bound. Vd is about 500 L.
Metabolism
Telmisartan is metabolized by conjugation to form a pharmacologically-inactive acylglucuronide. The glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine.
Elimination
Telmisartan t ½ is approximately 24 h and total plasma Cl is greater than 800 mL/min. After IV or oral administration, more than 97% is eliminated unchanged in feces via biliary excretion.
Special Populations
Hepatic Function ImpairmentPlasma concentrations are increased and absolute bioavailability approaches 100%.
GenderPlasma concentrations are generally 2 to 3 times higher in women than in men.
Indications and Usage
Treatment of hypertension.
Contraindications
Standard considerations.
Dosage and Administration
AdultsPO 20 to 80 mg/day; usual starting dose, 40 mg/day.
Storage/Stability
Store at room temperature (59° to 86°F).
Drug Interactions
DigoxinMay increase plasma levels of digoxin, that may increase toxicity.
LithiumPlasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic effects and adverse reactions of lithium.
Laboratory Test Interactions
None well documented.
Adverse Reactions
EENT
Sinusitis (3%); pharyngitis (1%).
GI
Diarrhea (3%).
Respiratory
Upper respiratory tract infection (7%).
Miscellaneous
Back pain (3%).
Precautions
WarningsPregnancyWhen used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible. |
Pregnancy
Category C (first trimester); Category D (second and third trimester).
Lactation
Undetermined.
Children
Safety and efficacy not established.
Renal Function
Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death.
Hepatic Function
Use with caution.
Black patients
Telmisartan may not be as effective in black patients.
Dialysis
Patients on dialysis may develop orthostatic hypotension.
Hypotension/Volume-depleted patients
Symptomatic hypotension may occur after telmisartan initiation in intravascularly volume-depleted patients (eg, those treated with diuretics). Correct these conditions prior to administration or use lower starting dose.
Overdosage
Symptoms
Hypotension, dizziness, tachycardia, bradycardia.
Patient Information
- Instruct patient to take the medication as prescribed at the same time each day.
- Inform patient that telmisartan controls but does not cure hypertension.
- Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
- Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
- Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
- Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
- Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
- Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
- Advise women to contact health care provider if pregnant, planning to become pregnant, or breast-feeding. Inform the patient of potential harm to the fetus.
| Link to Page | Print Page | Email Page | Add to List |
More Telmisartan resources
Telmisartan - Includes detailed dosage instructions.
